These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 18463035

  • 1. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL, Hu B, Reed S, Mirocha J, Adams JS.
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [Abstract] [Full Text] [Related]

  • 2. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 3. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [Abstract] [Full Text] [Related]

  • 4. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 5. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Sawka AM, Ioannidis G, Papaioannou A, Thabane L, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Kouroukis T, Adachi JD.
    J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
    [Abstract] [Full Text] [Related]

  • 6. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 7. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 9. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 10. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH, Adams-Huet B, Poindexter JR, Maalouf NM.
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [Abstract] [Full Text] [Related]

  • 11. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D insufficiency does not affect response of bone mineral density to alendronate.
    Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE.
    Osteoporos Int; 2009 Jul 30; 20(7):1259-66. PubMed ID: 19043656
    [Abstract] [Full Text] [Related]

  • 13. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 30; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome.
    Ferlin A, Selice R, Di Mambro A, Ghezzi M, Di Nisio A, Caretta N, Foresta C.
    Osteoporos Int; 2015 Aug 30; 26(8):2193-202. PubMed ID: 25963234
    [Abstract] [Full Text] [Related]

  • 18. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD, Farahmand P, Faber H, Dorst A.
    Rheumatol Int; 2009 Jan 30; 29(3):311-5. PubMed ID: 18762944
    [Abstract] [Full Text] [Related]

  • 19. Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia.
    Tanzy ME, Camacho PM.
    Endocr Pract; 2011 Jan 30; 17(6):873-9. PubMed ID: 21550960
    [Abstract] [Full Text] [Related]

  • 20. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.
    Pediatr Endocrinol Rev; 2008 Oct 30; 6 Suppl 1():144-8. PubMed ID: 19337169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.